You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Hodgkin's

Showing 26 - 50 of 4,440
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in Changsha, Suzhou (U16)

Recruiting
  • Relapsed or Refractory Non-Hodgkin's Lymphoma
  • Changsha, Hunan, China
  • +1 more
Mar 13, 2023

Non-hodgkin Lymphoma Trial (CD38-SADA:177Lu-DOTA Complex)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • CD38-SADA:177Lu-DOTA Complex
  • (no location specified)
Aug 15, 2023

Advanced Classical Hodgkin's Lymphoma in Brazil Treated With

Not yet recruiting
  • Hodgkin Lymphoma
  • No Intervention
  • Salvador, Bahia, Brazil
  • +5 more
Oct 23, 2023

Quality of Life in Adult and Pediatric Nodular

Recruiting
  • Nodular Lymphocyte-Predominant Hodgkin Lymphoma
    • Aurora, Colorado
    • +1 more
    Oct 27, 2023

    Glioblastoma, Squamous Cell Carcinoma, Hodgkin Lymphoma Trial (AVM0703, Hydrocortisone, Proton pump inhibitor)

    Available
    • Glioblastoma
    • +13 more
    • (no location specified)
    Jul 26, 2023

    Hodgkin Lymphoma Trial in Moscow (Nivolumab)

    Recruiting
    • Hodgkin Lymphoma
    • Moscow, Russian Federation
      The Federal Budget-Funded Institution National Medical Surgical
    Oct 31, 2022

    Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

    Recruiting
    • Relapsed or Refractory Hodgkin Lymphoma
    • Beijing, Beijing, China
      Han wei dong
    Jun 14, 2023

    Non-hodgkin's Lymphoma Trial in Beijing (GNC-038)

    Recruiting
    • Non-hodgkin's Lymphoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Jan 12, 2023

    Non-Hodgkin Lymphoma Trial in Taiwan, United States (CHO-H01)

    Recruiting
    • Non-Hodgkin Lymphoma
    • CHO-H01
    • The Woodlands, Texas
    • +7 more
    Jul 10, 2023

    Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral Trial (SGN-35T)

    Not yet recruiting
    • Lymphoma, T-Cell, Cutaneous
    • +5 more
    • (no location specified)
    Nov 2, 2023

    Hodgkin Lymphoma, Relapse, Refractory Trial in Chapel Hill (Chemotherapy, Cell infusion)

    Not yet recruiting
    • Hodgkin Lymphoma
    • +2 more
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center
    Oct 13, 2023

    Non-Hodgkin Lymphoma, Hodgkin Lymphoma Trial in Minneapolis (drug, procedure, biological, radiation)

    Recruiting
    • Non-Hodgkin Lymphoma
    • Hodgkin Lymphoma
    • Minneapolis, Minnesota
      Masonic Cancer Center, University of Minnesota
    Jan 25, 2023

    Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed Trial in United States (MT-601)

    Recruiting
    • Non-Hodgkin Lymphoma, Adult
    • +3 more
    • Duarte, California
    • +3 more
    Apr 4, 2023

    B-cell Non Hodgkin Lymphoma Trial (Odronextamab, Loncastuximab tesirine, Rituximab)

    Not yet recruiting
    • B-cell Non Hodgkin Lymphoma
    • (no location specified)
    Aug 7, 2023

    Non Hodgkin Lymphoma Trial in New York, Clayton, Frankston (IPH6501)

    Not yet recruiting
    • Non Hodgkin Lymphoma
    • New York, New York
    • +2 more
    Oct 12, 2023

    Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in China (AXT-1003)

    Not yet recruiting
    • Relapsed or Refractory Non-Hodgkin's Lymphoma
    • Beijing, China
    • +3 more
    Jul 20, 2023

    B-cell Non-Hodgkin's Lymphoma Trial (SHR-A1912; R-Chemo)

    Not yet recruiting
    • B-cell Non-Hodgkin's Lymphoma
    • SHR-A1912; R-Chemo
    • (no location specified)
    Oct 23, 2023

    Hodgkin Lymphoma Trial in Houston (Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab)

    Not yet recruiting
    • Hodgkin Lymphoma
    • Brentuximab vedotin
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jun 20, 2023

    LY007 for r/r B-NHL and Exploration of Novel CAR-T Translational

    Not yet recruiting
    • Relapsed Non-Hodgkin Lymphoma
      • (no location specified)
      Sep 19, 2023

      Recurrent/Refractory Classical Hodgkin's Lymphoma Trial in Tianjin (AK105,Anrotinib HCl)

      Enrolling by invitation
      • Recurrent/Refractory Classical Hodgkin's Lymphoma
      • AK105，Anrotinib hydrochloride
      • Tianjin, Tianjin, China
        Tianjin Medical University Cancer Insititute & Hospital
      Jan 12, 2023

      Lymphoma, Non-Hodgkin Trial in Perth (DZD8586)

      Not yet recruiting
      • Lymphoma, Non-Hodgkin
      • Perth, Western Australia, Australia
        Linear Clinical Research Ltd
      Apr 20, 2023

      Hodgkin Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma Trial in Rochester (drug, genetic, other)

      Withdrawn
      • Hodgkin Lymphoma
      • +4 more
      • Rochester, Minnesota
        Mayo Clinic
      Nov 28, 2022

      Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)

      Not yet recruiting
      • Relapsed/Refractory Non-Hodgkin Lymphoma
      • Duarte, California
      • +1 more
      Oct 13, 2023

      B-cell Non-Hodgkin's Lymphoma Trial (IMM0306, Lenalidomide capsule)

      Not yet recruiting
      • B-cell Non-Hodgkin's Lymphoma
      • (no location specified)
      Mar 6, 2023

      DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

      Not yet recruiting
      • DLBCL - Diffuse Large B Cell Lymphoma
      • +6 more
      • Bridging radiation therapy
      • +2 more
      • (no location specified)
      Jan 4, 2023